ea0070aep626 | Pituitary and Neuroendocrinology | ECE2020
Minczeles Noémie
, van Eijck CHJ
, van Gils MJ
, van Velthuysen MF
, Nieveen van Dijkum EJM
, Feelders Richard
, de Herder Wouter W
, Brabander* T
, Hofland* Hans
Introduction: Pancreatic neuroendocrine neoplasm (pNEN) patients often present with locally advanced or metastatic disease. The objective response rate of peptide receptor radionuclide therapy (PRRT) in pNENs is 55%. Therefore, PRRT may be a possibility for patients who are not eligible for upfront curative surgery.Aims: To assess the potency of PRRT to render locally advanced or oligometastatic pNENs resectable and to evaluate the effect of surgery afte...